Evidence map›Paper›PMID 34368633›Full record

ArticleJournal of Alzheimer's disease reports2021

RRY Inhibits Amyloid-β

Xicui Sun, Songwei Duan, Anna Cao, Bryan Villagomez, Runxuan Lin, Hongxia Chen, Liya Pi, Bin Ren, Rong Chen, Minjie Chen and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Xicui SunDepartment of Neurology, Sun Yat-sen University, Guangzhou, Guangdong, China.
Songwei DuanDepartment of Neurology, Sun Yat-sen University, Guangzhou, Guangdong, China.
Anna CaoDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Bryan VillagomezDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Runxuan LinDepartment of Neurology, Sun Yat-sen University, Guangzhou, Guangdong, China.
Hongxia ChenDepartment of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Liya PiDepartment of Pediatrics in College of Medicine, University of Florida, Gainesville, FL, USA.
Bin RenDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Rong ChenDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Minjie ChenDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Zhekang YingThe Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Shenyun FangDepartment of Physiology, University of Maryland, Baltimore, Maryland, USA.
Qi CaoDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · USSun Yat-sen University · CNUniversity of Alabama at Birmingham · USUniversity of Florida · US

Funding

18F Proline Preclinical PET Imaging In The Diagnosis of Early Stage Alcoholic Liver FibrosisK08AA024895 · NIAAA · UNIVERSITY OF MARYLAND BALTIMORE · PI CAO, QI · 2017 to 2021
$953k
NIAAA NIH HHS K08 AA024895
6 · The paper itself

Abstract

backgroundCurrent understanding of amyloid-β protein (Aβ) aggregation and toxicity provides an extensive list of drugs for treating Alzheimer's disease (AD); however, one of the most promising strategies for its treatment has been tri-peptides.

objectiveThe aim of this study is to examine those tri-peptides, such as Arg-Arg-Try (RRY), which have the potential of Aβ

methodsIn the present study,

resultsIn the

conclusionSuch converging outcomes from three consecutive studies lead us to conclude that RRY is a preferred inhibitor of Aβ

Indexed as

Alzheimer’s diseaseamyloid-βAPP/PS1 transgenic micehigh throughput screeningsmall peptide

Identifiers

PMID34368633
PMCPMC8293670
OpenAlexW3164371311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.